Peginterferon/Ribavirin Cost Balanced By Increased Efficacy - Schering

Cost-effectiveness arguments will likely underpin European marketing of Schering-Plough's ViraferonPeg in combination with Rebetol for treatment of chronic hepatitis C, and could be used in U.S. marketing when the combination is approved by FDA.